with HER2 listed as the leading target candidate, thus highlighting the opportunity for ANGLE's HER2 assay to support drug trials. The full Phase 2 study of BB-1701 has not yet completed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback